Lantheus (NASDAQ:LNTH) Given New $100.00 Price Target at Mizuho

Lantheus (NASDAQ:LNTH) had its price objective raised by Mizuho from $90.00 to $100.00 in a research report report published on Friday morning, Benzinga reports. The brokerage currently has a buy rating on the medical equipment provider’s stock.

Other equities research analysts have also recently issued research reports about the company. Truist Financial reissued a buy rating and issued a $82.00 price target (up previously from $80.00) on shares of Lantheus in a research note on Monday, February 26th. StockNews.com raised shares of Lantheus from a hold rating to a buy rating in a research report on Saturday, January 13th. B. Riley boosted their price target on shares of Lantheus from $95.00 to $99.00 and gave the stock a buy rating in a research report on Thursday, April 18th. Finally, JMP Securities reaffirmed a market outperform rating and issued a $100.00 price objective on shares of Lantheus in a research note on Friday, February 23rd. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, Lantheus currently has a consensus rating of Moderate Buy and an average price target of $103.14.

Lantheus Trading Down 3.4 %

Shares of Lantheus stock traded down $2.65 on Friday, hitting $75.53. The stock had a trading volume of 1,838,111 shares, compared to its average volume of 909,698. The stock has a 50 day moving average of $62.67 and a 200 day moving average of $62.83. The firm has a market capitalization of $5.18 billion, a P/E ratio of 11.53 and a beta of 0.52. Lantheus has a twelve month low of $50.20 and a twelve month high of $100.85. The company has a debt-to-equity ratio of 0.59, a quick ratio of 5.45 and a current ratio of 4.84.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.33 by $0.26. The firm had revenue of $354.00 million during the quarter, compared to analysts’ expectations of $350.44 million. Lantheus had a net margin of 33.72% and a return on equity of 54.10%. Sell-side analysts expect that Lantheus will post 5.96 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the firm’s stock in a transaction on Wednesday, March 6th. The stock was purchased at an average cost of $0.95 per share, with a total value of $57,409,487.05. Following the completion of the purchase, the insider now owns 116,773,394 shares in the company, valued at approximately $110,934,724.30. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, Director Mary Anne Heino sold 93,863 shares of the company’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the transaction, the director now directly owns 251,643 shares of the company’s stock, valued at $16,434,804.33. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of the business’s stock in a transaction that occurred on Wednesday, March 6th. The stock was purchased at an average price of $0.95 per share, for a total transaction of $57,409,487.05. Following the completion of the acquisition, the insider now owns 116,773,394 shares in the company, valued at $110,934,724.30. The disclosure for this purchase can be found here. Insiders have sold a total of 94,545 shares of company stock valued at $6,169,936 over the last ninety days. 1.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. UMB Bank n.a. increased its position in shares of Lantheus by 161.4% during the first quarter. UMB Bank n.a. now owns 400 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 247 shares in the last quarter. Tucker Asset Management LLC increased its holdings in Lantheus by 239.0% during the 3rd quarter. Tucker Asset Management LLC now owns 400 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 282 shares in the last quarter. Principal Securities Inc. purchased a new stake in shares of Lantheus in the fourth quarter worth approximately $28,000. First Horizon Advisors Inc. lifted its holdings in shares of Lantheus by 97.0% in the third quarter. First Horizon Advisors Inc. now owns 457 shares of the medical equipment provider’s stock valued at $32,000 after purchasing an additional 225 shares in the last quarter. Finally, Fidelis Capital Partners LLC purchased a new position in shares of Lantheus during the first quarter valued at approximately $34,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.